



(51) International Patent Classification:

<i>A61K 38/47</i> (2006.01)	<i>A61K 31/37</i> (2006.01)
<i>A61K 9/107</i> (2006.01)	<i>A61K 31/42</i> (2006.01)
<i>A61K 9/127</i> (2006.01)	<i>A61K 31/573</i> (2006.01)
<i>A61K 47/48</i> (2006.01)	<i>A61K 31/706</i> (2006.01)
<i>A61K 9/50</i> (2006.01)	<i>A61K 31/7068</i> (2006.01)
<i>A61K 9/51</i> (2006.01)	<i>A61K 31/7076</i> (2006.01)
<i>A61K 31/337</i> (2006.01)	<i>A61K 31/7088</i> (2006.01)

(21) International Application Number:

PCT/US2013/032684

(22) International Filing Date:

15 March 2013 (15.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/686,429	4 April 2012 (04.04.2012)	US
61/714,719	16 October 2012 (16.10.2012)	US

(71) Applicant: HALOZYME, INC. [US/US]; 11388 Sorrento Valley Road, San Diego, CA 92121 (US).

(72) Inventors: MANEVAL, Daniel, C.; 12892 Baywind Point, San Diego, CA 92130 (US). SHEPARD, H., Michael; 4637 Pavlov Ave., San Diego, CA 92122 (US). THOMPSON, Curtis, B.; 10355 Veracruz Court, San Diego, CA 92124 (US).

(74) Agents: SEIDMAN, Stephanie, L. et al.; McKENNA LONG & ALDRIDGE LLP, 4435 Eastgate Mall, Suite 400, San Diego, CA 92121 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMBINATION THERAPY WITH AN ANTI - HYALURONAN AGENT AND A TUMOR - TARGETED TAXANE

(57) Abstract: Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.

